AcquisitionsMar 29, 2026, 08:10 PM
Gilead Sciences to Acquire Arcellx for $115 per Share Plus Contingent Value Right
AI Summary
Gilead Sciences has entered into an agreement to acquire Arcellx for $115.00 per share in cash, plus one contingent value right (CVR) representing the right to receive $5.00 per CVR upon achievement of a specified milestone. The acquisition will be made via a tender offer for all outstanding shares of Arcellx common stock.
Key Highlights
- Gilead will acquire Arcellx through a tender offer.
- The offer includes $115.00 per share in cash plus a contingent value right of $5.00 per share.
- The tender offer will remain open for a minimum of 20 business days.